Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | Predicting DCIS recurrence: insights from the E4 112 trial

Rick Baehner, MD, from Exact Sciences, discusses the ECOG-ACRIN E4112 (NCT02352883), which focuses on using the DCIS score, a 12-gene score, to predict the risk of ipsilateral breast recurrence in patients who underwent successful wide local excision for ductal carcinoma in situ (DCIS). The trial differentiates patients into low, intermediate, or high-risk categories based on the DCIS score, with recommendations for radiotherapy accordingly. Patients with low-risk scores were advised against radiotherapy, while those with intermediate or high-risk scores were recommended radiotherapy. The outcomes at five years were compared between these groups. The findings suggest that patients with a low-risk DCIS score, who did not receive radiotherapy, had a low risk of ipsilateral breast events (less than 6% at 5.5%), comparable to patients with higher risk scores who received radiotherapy after wide local excision. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.